NCT00720629 2014-07-18Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated8 enrolled 11 charts